Published in PLoS One on February 13, 2012
High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science (2013) 8.24
Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One (2014) 2.20
Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis (2013) 2.00
High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr (2013) 1.97
The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission. J Acquir Immune Defic Syndr (2013) 1.85
Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV (2015) 1.77
Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med (2013) 1.73
Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS (2012) 1.51
Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. Int J Tuberc Lung Dis (2014) 1.46
Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep (2013) 1.36
HIV treatment and care in resource-constrained environments: challenges for the next decade. J Int AIDS Soc (2012) 1.21
Addressing the Achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis (2014) 1.17
Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as prevention. J Acquir Immune Defic Syndr (2013) 1.11
Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations. J Acquir Immune Defic Syndr (2013) 1.09
Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs. PLoS One (2012) 1.08
HIV treatment as prevention: the key to an AIDS-free generation. J Food Drug Anal (2013) 1.05
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med (2014) 1.03
Balancing efficiency, equity and feasibility of HIV treatment in South Africa - development of programmatic guidance. Cost Eff Resour Alloc (2013) 1.02
Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990-2013. PLoS One (2015) 1.02
A three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. J Int AIDS Soc (2014) 0.99
Process monitoring of an HIV treatment as prevention program in British Columbia, Canada. J Acquir Immune Defic Syndr (2014) 0.96
Global response to HIV: treatment as prevention, or treatment for treatment? Clin Infect Dis (2014) 0.94
How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS One (2013) 0.92
Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. J Infect Dis (2013) 0.91
Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep (2014) 0.87
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health (2013) 0.87
The cost of providing combined prevention and treatment services, including ART, to female sex workers in Burkina Faso. PLoS One (2014) 0.87
Young, Online and in the Dark: Scaling Up HIV Testing among MSM in ASEAN. PLoS One (2015) 0.86
Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature Review. Health Econ (2016) 0.85
Modeling the implementation of universal coverage for HIV treatment as prevention and its impact on the HIV epidemic. Curr HIV/AIDS Rep (2014) 0.85
Enhancing the benefits of antiretroviral therapy in Vietnam: towards ending AIDS. Curr HIV/AIDS Rep (2014) 0.84
Impact and Cost of the HIV/AIDS National Strategic Plan for Mozambique, 2015-2019-Projections with the Spectrum/Goals Model. PLoS One (2015) 0.83
Massive benefits of antiretroviral therapy in Africa. J Infect Dis (2013) 0.82
The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. PLoS Med (2015) 0.80
Empowering patients to link to care and treatment: qualitative findings about the role of a home-based HIV counselling, testing and linkage intervention in South Africa. AIDS Care (2015) 0.80
Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. Retrovirology (2013) 0.79
Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda. BMC Infect Dis (2017) 0.78
Diagnostic accuracy of the WHO clinical staging system for defining eligibility for ART in sub-Saharan Africa: a systematic review and meta-analysis. J Int AIDS Soc (2014) 0.78
Using HIV Sequence and Epidemiologic Data to Assess the Effect of Self-referral Testing for Acute HIV Infection on Incident Diagnoses in San Diego, California. Clin Infect Dis (2016) 0.78
Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One (2016) 0.77
The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials. HIV Clin Trials (2014) 0.77
A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes. Clinicoecon Outcomes Res (2015) 0.76
Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure. AIDS Res Ther (2012) 0.75
Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS. Health Econ Rev (2017) 0.75
Bibliometric trends of health economic evaluation in Sub-Saharan Africa. Global Health (2016) 0.75
A practical online tool to estimate antiretroviral coverage for HIV infected and susceptible populations needed to reduce local HIV epidemics. Sci Rep (2016) 0.75
Capsule commentary on Long and Stavert, portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. J Gen Intern Med (2013) 0.75
Cost-effectiveness analysis of the national decentralization policy of antiretroviral treatment programme in Zambia. Cost Eff Resour Alloc (2017) 0.75
Protocol for a Randomized Controlled Trial Evaluating Mobile Text Messaging to Promote Retention and Adherence to Antiretroviral Therapy for People Living With HIV in Burkina Faso. JMIR Res Protoc (2016) 0.75
HIV treatment as prevention: contradictory perspectives from dynamic mathematical models. ScientificWorldJournal (2014) 0.75
Highlights of the International Congress on Drug Therapy in HIV Infection, 23-26 October 2016, Glasgow, UK. J Virus Erad (2017) 0.75
Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. Lancet Glob Health (2017) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet (2008) 11.20
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS (2006) 9.45
Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health (2010) 8.81
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Effect of serotesting with counselling on condom use and seroconversion among HIV discordant couples in Africa. BMJ (1992) 5.66
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
HIV prevention before HAART in sub-Saharan Africa. Lancet (2002) 5.55
Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr (2005) 4.96
Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet (2008) 4.70
The costs and effectiveness of four HIV counseling and testing strategies in Uganda. AIDS (2009) 4.45
Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med (2006) 4.34
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS (2010) 4.20
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet (2004) 4.19
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis (2004) 4.17
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
Public health. Reassessing HIV prevention. Science (2008) 4.06
Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS (2010) 4.05
Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making? PLoS Med (2009) 4.05
Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis (2002) 3.58
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA (2006) 2.51
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science (2010) 2.19
Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med (2010) 2.10
Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS (2010) 2.04
Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA (2010) 1.98
Economic returns to investment in AIDS treatment in low and middle income countries. PLoS One (2011) 1.98
The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy (2009) 1.94
Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics (2011) 1.89
The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr (2007) 1.88
Treating our way out of the HIV pandemic: could we, would we, should we? Lancet (2008) 1.78
The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr (2011) 1.67
The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS One (2011) 1.67
Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet (2010) 1.46
HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS (2010) 1.38
Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. AIDS (2010) 1.34
Critical choices in financing the response to the global HIV/AIDS pandemic. Health Aff (Millwood) (2009) 1.33
Modeling the joint epidemics of TB and HIV in a South African township. J Math Biol (2008) 1.31
Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. PLoS One (2012) 1.18
The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008. Curr Opin HIV AIDS (2010) 1.16
HIV/AIDS. The great funding surge. Science (2008) 1.11
The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc (2011) 1.11
Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol (2008) 1.09
Zero New HIV Infections, Zero Discrimination, and Zero AIDS-Related Deaths: Feasible Goals or Ambitious Visions on the Occasion of the World AIDS Day? Int J Prev Med (2012) 0.98
HIV/AIDS prevention and treatment. Lancet (2002) 0.84
Costing human rights and community support interventions as a part of universal access to HIV treatment and care in a Southern African setting. Curr HIV Res (2011) 0.82
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med (2003) 24.99
The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet (2006) 11.06
The burden of malaria mortality among African children in the year 2000. Int J Epidemiol (2006) 6.64
Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med (2009) 5.93
HIV prevention before HAART in sub-Saharan Africa. Lancet (2002) 5.55
Global incidence of multidrug-resistant tuberculosis. J Infect Dis (2006) 5.42
The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis (2003) 5.09
The population dynamics and control of tuberculosis. Science (2010) 5.08
Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. AIDS (2003) 4.87
Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. Bull World Health Organ (2002) 4.47
HIV development assistance and adult mortality in Africa. JAMA (2012) 4.14
Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health (2007) 4.13
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis (2003) 4.10
Investment in HIV/AIDS programs: does it help strengthen health systems in developing countries? Global Health (2008) 4.10
HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med (2012) 4.08
Public health. Reassessing HIV prevention. Science (2008) 4.06
The HIV-associated tuberculosis epidemic--when will we act? Lancet (2010) 3.82
Implementation science for the US President's Emergency Plan for AIDS Relief (PEPFAR). J Acquir Immune Defic Syndr (2011) 3.77
Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One (2011) 3.57
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health (2008) 3.32
Diabetes and the risk of tuberculosis: a neglected threat to public health? Chronic Illn (2007) 3.31
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Costs and financial feasibility of malaria elimination. Lancet (2010) 3.15
To retain or remove user fees?: reflections on the current debate in low- and middle-income countries. Appl Health Econ Health Policy (2006) 3.06
Tuberculosis incidence in prisons: a systematic review. PLoS Med (2010) 2.96
AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 2.92
HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis (2006) 2.82
National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS (2006) 2.82
Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr (2009) 2.81
Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis (2005) 2.80
Impact of malaria control on childhood anaemia in Africa -- a quantitative review. Trop Med Int Health (2004) 2.80
Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science (2002) 2.65
HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res (2007) 2.55
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis (2003) 2.49
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
Malaria control and elimination in Sri Lanka: documenting progress and success factors in a conflict setting. PLoS One (2012) 2.34
Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J Acquir Immune Defic Syndr (2010) 2.33
Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis (2002) 2.33
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol (2013) 2.31
Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa. PLoS One (2008) 2.31
A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol (2009) 2.20
Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ (2006) 2.20
Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep (2002) 2.14
What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world? Curr HIV Res (2007) 2.12
Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS One (2010) 2.12
Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS (2003) 2.11
The effect of health insurance on medical care utilization and implications for insurance expansion: a review of the literature. Med Care Res Rev (2005) 2.11
Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health (2005) 2.09
Use of cost-effectiveness analysis to evaluate new technologies in orthopaedics. The case of alternative bearing surfaces in total hip arthroplasty. J Bone Joint Surg Am (2006) 2.07
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr (2008) 2.04
Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data. Lancet (2013) 2.03
Child coverage with mosquito nets and malaria treatment from population-based surveys in african countries: a baseline for monitoring progress in roll back malaria. Am J Trop Med Hyg (2004) 2.01
Eliminating human tuberculosis in the twenty-first century. J R Soc Interface (2008) 2.00
Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk? Am J Trop Med Hyg (2004) 1.98
Assessing the efficiency of HIV prevention around the world: methods of the PANCEA project. Health Serv Res (2004) 1.96
Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS (2007) 1.94
The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy (2009) 1.94
Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ (2009) 1.91
Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: Simulation results. Sex Transm Dis (2006) 1.91
Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics (2011) 1.89
Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS (2010) 1.83
HIV prevention programmes for female sex workers in Andhra Pradesh, India: outputs, cost and efficiency. BMC Public Health (2005) 1.83
Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr (2012) 1.78
HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med (2012) 1.76
Scale-up and continuation of antiretroviral therapy in South African treatment programs, 2005-2009. J Acquir Immune Defic Syndr (2011) 1.76
Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int (2011) 1.75
Estimating the number of insecticide-treated nets required by African households to reach continent-wide malaria coverage targets. JAMA (2007) 1.74
What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis (Edinb) (2003) 1.72
Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India. BMC Health Serv Res (2008) 1.69
Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007. BMC Infect Dis (2010) 1.67
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS (2014) 1.67
Cost and efficiency of public sector sexually transmitted infection clinics in Andhra Pradesh, India. BMC Health Serv Res (2005) 1.66
Methodological and policy limitations of quantifying the saving of lives: a case study of the Global Fund's approach. PLoS Med (2013) 1.65
Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials?: A modeling study. J Acquir Immune Defic Syndr (2004) 1.65
Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ (2011) 1.64
Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV prevention trial outcomes. AIDS (2003) 1.63
The effect of diagnostic delays on the drop-out rate and the total delay to diagnosis of tuberculosis. PLoS One (2008) 1.61
New WHO HIV treatment and prevention guidelines. Lancet (2009) 1.59
Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect (2010) 1.59
Survey of children accessing HIV services in a high prevalence setting: time for adolescents to count? Bull World Health Organ (2009) 1.59